Prelude Therapeutics, Inc. PRLD 深 沪
已收盘 04-02 16:00:00 美东时间
3.46
+0.010
+0.29%
华盛通- 最 高3.66
- 今 开3.30
- 成交量 10.57万股
- 最 低 3.27
- 昨 收 3.45
- 总市值 2.18亿
- 52周最高 4.22
- 市盈率 静 --
- 换手率 0.17%
- 52周最低 0.6567
- 委 比 -44.14%
- 总股本 6300.22万
- 历史最高 95.375
- 量 比 0.76
- 振 幅 11.30%
- 历史最低 0.6101
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Prelude Therapeutics Announces Poster With Preclinical Data On Its Oral KAT6A Selective Degrader Accepted For Presentation At American Association For Cancer Research Annual Meeting 2026
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company's oral KAT6A selective degrader (PRT13722) has been accepted for
03-18 04:33
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Prelude Therapeutics shares are trading higher. The company reported Q4 financial results.
Prelude Therapeutics shares are trading higher. The company reported Q4 financi...
03-11 01:39
Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program
Prelude Therapeutics ( ($PRLD) ) has issued an update. Prelude Therapeutics rep...
03-10 20:47
Prelude Therapeutics Earnings Report: Q4 Overview
Prelude Therapeutics (NASDAQ:PRLD) announced its Q4 earnings on Tuesday, March ...
03-10 19:40
Prelude Therapeutics Q4 EPS $(0.20) Misses $(0.03) Estimate, Sales $5.640M Miss $35.000M Estimate
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.03) by 566.67 percent. This is a 45.95 percent increase over losses of $(0.37) per
03-10 19:38
Prelude Therapeutics FY2025 net loss fell 22% to USD 99.5 million
Prelude Therapeutics FY2025 net loss fell 22% to USD 99.5 million Prelude Therapeutics reported FY 2025 revenue of USD 12.14 million, up 73%. FY 2025 R&D expense fell 20% to USD 94.3 million, driven by lower stock-based compensation and reduced costs tied to discontinued clinical trials. FY 2025 G&A
03-10 19:12
Prelude Therapeutics reports $99.5 mln net loss for 2025
Prelude Therapeutics reports $99.5 mln net loss for 2025 Overview Precision oncology firm reported a net loss of $99.5 mln for 2025 Company received FDA clearance for IND application for PRT12396 Cash runway expected into Q2 2027 with $106 mln in cash and equivalents Outlook Prelude anticipates Phas
03-10 19:08
BRIEF-Prelude Therapeutics FY EPS USD -1.29
BRIEF-Prelude Therapeutics FY EPS USD -1.29 Mar 10 (Reuters) - Prelude Therapeutics FY operating expenses USD 116.706 million. FY income from operations USD -104.566 million FY net income USD -99.498 million
03-10 19:01
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
Prelude Therapeutics reported financial results for 2025, highlighting a cash runway extending into Q2 2027. The company announced FDA clearance for its mutant-selective JAK2V617F inhibitor PRT12396 and plans to initiate Phase 1 trials for PRT12396 in high-risk PV and MF patients in Q2 2026. Additionally, the KAT6A degrader PRT13722 is expected to enter clinical development later in 2026. Notably, R&D expenses decreased, reflecting reduced costs ...
03-10 11:01
